Focus: BioCryst is a small-molecule pharmaceutical company headquartered in Durham, NC, focused on rare diseases in neurology and infectious diseases. The company is publicly traded (BCRX) with a heavily concentrated revenue base from its lead product ORLADEYO.
Profile data last refreshed 59m ago · AI intelligence enriched 2mo ago
Stable — net -1 jobs in 30d
6 added, 7 removed. Backfill posture.
BioCryst offers high-impact rare disease work with a stable lead product, but the single-revenue-stream model and cash burn create material career risk; best suited for R&D scientists seeking pipeline exposure with tolerance for restructuring scenarios.
Help build intelligence for BioCryst Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BioCryst Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole revenue driver; plasma kallikrein inhibitor with long LOE runway; $52M Part D spending indicates established market presence and reimbursement support.
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings Sahm
Island Pharma hires ex-BioCryst leader to accelerate Galidesivir biodefence push - TipRanks
Island Pharma hires ex-BioCryst leader to accelerate Galidesivir biodefence push TipRanks
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm GuruFocus
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm GuruFocus
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Benzinga
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings Benzinga
BioCryst scraps eye drug to focus on rare diseases - Fierce Biotech
BioCryst scraps eye drug to focus on rare diseases Fierce Biotech
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials.
Long-term prophylactic treatment preferences and willingness to switch therapy in individuals with hereditary angioedema.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo